The Cardiac Ledger
All letters
Breakthrough Lost Its Medicare Edge
Since October 1, 2026, Breakthrough designation no longer exempts most devices from the substantial clinical improvement test for NTAP and pass-through. RAPID coverage is still a proposal. A 2027 plan has to carry those two facts on separate timelines.
The TAVR Rule Left One Group of Patients Out
CMS's September 10, 2026 TAVR decision covers symptomatic severe aortic stenosis without a study requirement, while asymptomatic patients are covered only in a CMS-approved study. The two timelines differ, and plans should treat them separately.
The Buyer Already on Your Cap Table
In cardiovascular MedTech the early strategic investor is often the natural acquirer. The terms of a strategic round can shape how many bidders compete at exit and how proceeds divide, so they deserve the same scrutiny a board gives the valuation.

